Venetoclax Plus Dose-Adjusted R-EPOCH Yields Durable Responses in Richter Syndrome
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Researchers sought to determine whether brentuximab vedotin with bendamustine would be effective in pediatric patients with relapsed or refractory Hodgkin lymphoma.
Two novel analytical approaches can accurately indicate the course of multiple myeloma, according to researchers.
The study included 203 patients with steroid-resistant acute GVHD who were treated at 10 centers in China between September 2014 and March 2019.
Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.
Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.
Researchers sought to determine whether there are disparities by race/ethnicity and socioeconomic status in survival outcomes of children with ALL.
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.